Home » Advanced Oncotherapy (AVO) » Advanced Oncotherapy (AVO) – Directorate Change

Advanced Oncotherapy (AVO) – Directorate Change

AVO1Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following the continued successful development of the Company’s first LIGHT system and the recent industrialisation agreement with Thales, the Board has decided to realign the roles and responsibilities of the Executive team to add additional focus to both operational functions and ongoing sales and business development.

As a result, and with immediate effect, Michael Sinclair, currently Executive Chairman, will become Chief Executive Officer and Executive Chairman; Sanjeev Pandya, currently Chief Executive Officer, will become Executive Vice President for Global Business Development and will remain on the Board of the Company. Nicolas Serandour, currently Chief Financial Officer, will become Chief Operating and Financial Officer.

Commenting, Sanjeev Pandya, said: “The agreement with Thales marked a shift in the business from just focussing on the development of our first LIGHT system, to the ongoing commercial roll-out of our game-changing technology. The future commercial development of the business will be critical to the long-term success and value creation within the Company and I am delighted to be focussing my skills on global sales for the LIGHT system and general business development.”

Dr. Michael Sinclair, Chairman and Chief Executive, commented: “We have agreed as a Board that we are now at a stage where we need to apply renewed focus on the development of an ongoing sales pipeline for our LIGHT system outside of our agreement with Sinophi. Sanjeev’s skills in this area will be deployed very effectively and I am pleased he has decided to take on this new challenge. Nicolas’ additional operational responsibility reflects what has already become a growing part of his role and I am delighted that he will be able to combine this with his careful management of the business’s finances. As shareholders know, I have always performed an active executive role as Chairman and I now look forward to continue working with the team as Chief Executive.”

Advanced Oncotherapy Plc


Dr. Michael Sinclair, Chairman & CEO

Tel: +44 20 3617 8728

Sanjeev Pandya, EVP for Global Business Development

Nicolas Serandour, COO & CFO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Belliss / Elliot Hance

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001


Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.